Non-Hodgkin lymphoma Posts - Page 2 of 44 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Posted by on Apr 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and modified non-Hodgkin lymphoma (NHL) Berlin-Frankfurt-Münster-90 (NHL-BFM-90; cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, methotrexate, vindesine, dexamethasone, cytarabine)...

Read More

Comparing the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma versus the general population.

Comparing the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma versus the general population.

Posted by on Apr 10, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma (NHL) versus the general population. The data showed that survivors of NHL had an increased risk of developing second primary cancers over time compared to the general population. Some background NHL is cancer that starts...

Read More

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Posted by on Feb 6, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to other lines of treatment....

Read More

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Posted by on Jan 23, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of radiotherapy (RT) for the treatment of patients with indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that RT was highly effective with manageable side effects in these patients. Some background Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells...

Read More

How are survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: A quality of life study

How are survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: A quality of life study

Posted by on Dec 5, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the health-related quality of life (HRQoL) 1 year after the diagnosis of diffuse large B-cell lymphoma (DLBCL). The study found that HRQoL is affected differently in women and men survivors of DLBCL 1 year after diagnosis and that aspects of HRQoL need to be addressed and managed in these...

Read More

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).   This study concluded that this treatment can be effective in these patients.   Some background Radiotherapy (RT) is an important treatment in managing patients...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor